Assessing the use of navigators for improvement of patient adherence to onabotulinumtoxinA

“We really felt that this was an important question to ask because we know that OAB therapy adherence is associated with improvements in urinary symptoms, quality of life, and decreased OAB-related health care costs,” says Ekene Enemchukwu, MD, MPH.

In this video, Ekene Enemchukwu, MD, MPH, discusses the background of the study, “Identifying navigator impact on utilization of onabotulinumtoxina as a 3rd line treatment in overactive bladder: A retrospective database study in the United States” This study was presented at the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction 2022 Winter Meeting. Enemchukwu is a pelvic reconstruction surgeon at Stanford Health Care, and an assistant professor of urology and obstetrics and gynecology at the Stanford University School of Medicine in California.